Alpha 2.0
Login Register
» Authors » Donatella Ieluzzi

Donatella Ieluzzi

Explore the profile of Donatella Ieluzzi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 220
Followers 0
Related Specialties
Gastroenterology
General Medicine
Science
Top 10 Co-Authors
Francesco Paolo Russo
Loreta A Kondili
Maria Giovanna Quaranta
Marco Massari
Massimo Puoti
Pierluigi Toniutto
Veronica Paon
Giuseppina Brancaccio
Anna Linda Zignego
Giovanna Fattovich
Published In
PLoS One
Hepatology
Dig Liver Dis
Liver Int
Gut
Affiliations
Soon will be listed here.
Recent Articles
1.
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort
Kondili L, Brancaccio G, Tosti M, Coco B, Quaranta M, Messina V, et al.
Int J Infect Dis . 2024 May; 146:107115. PMID: 38801968
Background And Aims: We aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN)...
2.
Hepatofugal portal flow is highly predictive of acute-on-chronic liver failure: A new hemodynamic patho-physiological hypothesis
Bevilacqua M, De Marco L, Stupia R, Cattazzo F, Zoncape M, Paon V, et al.
Dig Liver Dis . 2024 Jan; 56(9):1522-1528. PMID: 38281869
Background And Aims: Acute-on-chronic liver failure (ACLF) is a severe complication of advanced liver disease. A significant number of ACLF patients have not clear precipitating factors. The aim of the...
3.
Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies-A Case-Control Study
Ammendola S, Romeo S, Cattazzo F, Mantovani A, Ieluzzi D, Paon V, et al.
Int J Mol Sci . 2024 Jan; 25(2). PMID: 38255857
Twenty-nine patients with HCV infection (HCV+) and mixed cryoglobulinemia (MC+) were retrospectively selected and matched for age and sex with 31 HCV+ MC- patients. Biomarkers of cholestasis (direct bilirubin, alkaline...
4.
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort
Kondili L, Zanetto A, Quaranta M, Ferrigno L, Panetta V, Calvaruso V, et al.
United European Gastroenterol J . 2023 Nov; 12(3):352-363. PMID: 38032175
Background & Aims: Sustained virological response (SVR) by direct-acting antivirals (DAAs) may reverse the hypercoagulable state of HCV cirrhosis and the portal vein thrombosis (PVT) risk. We evaluated the incidence...
5.
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant
Mehta G, Riva A, Ballester M, Uson E, Pujadas M, Carvalho-Gomes A, et al.
Hepatol Commun . 2023 Oct; 7(11). PMID: 37870985
Background: Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are...
6.
Spur cells in liver cirrhosis are predictive of acute-on-chronic liver failure and liver-related mortality regardless of severe anaemia
Bevilacqua M, De Marco L, Stupia R, Dima F, Cattazzo F, Paon V, et al.
Intern Emerg Med . 2023 May; 18(5):1397-1404. PMID: 37212944
Chronic anaemia in advanced liver disease is a frequent finding. The aim was to explore the clinical impact of spur cell anaemia, a rare entity typically associated with end-stage of...
7.
The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study
Dalbeni A, Mantovani A, Zoncape M, Cattazzo F, Bevilacqua M, De Marco L, et al.
PLoS One . 2023 Feb; 18(2):e0281813. PMID: 36795664
Background And Purpose: Bacterial infections represent a major cause of morbidity and mortality in cirrhotic patients. Our aim was to assess the incidence of bacterial infections, in particular due to...
8.
Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience
Dalbeni A, Villani R, Bevilacqua M, Sacco F, Faccincani D, Cattazzo F, et al.
J Dig Dis . 2022 Jun; 23(5-6):324-330. PMID: 35700113
Objectives: Hepatitis C virus (HCV) infection is associated with an increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases. The impact of HCV eradication on the metabolic profile...
9.
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort
Kondili L, Monti M, Quaranta M, Gragnani L, Panetta V, Brancaccio G, et al.
Hepatology . 2021 Dec; 76(1):220-232. PMID: 34919289
Background And Aims: Mixed cryoglobulinemia is the most common HCV extrahepatic manifestation. We aimed to prospectively evaluate the cryoglobulinemic vasculitis (CV) clinical profile after a sustained virologic response (SVR) over...
10.
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort
Quaranta M, Ferrigno L, Tata X, DAngelo F, Massari M, Coppola C, et al.
Dig Liver Dis . 2021 Apr; 53(12):1603-1609. PMID: 33893040
Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs....